taphylococcus aureus has become a leading cause of community-and hospital-acquired pneumonia. Furthermore, infection with community-and health care-acquired strains of methicillinresistant S. aureus (MRSA) is increasingly common and limits antimicrobial options (13, 25, 29, 31) . Tedizolid phosphate (TR-701) is a novel oxazolidinone prodrug. The active moiety, tedizolid (TR-700), exhibits potent activity against Gram-positive bacteria, including MRSA (48). The goals of our studies were to identify the pharmacodynamic (PD) target (AUC/MIC ratio) for TR-700 against methicillin-susceptible S. aureus (MSSA) and MRSA strains in a neutropenic murine pneumonia model and compare the PD targets of TR-700 to that of the only FDA-approved oxazolidinone antibiotic, linezolid.
plicates were identical, and the final results were reported as the median value of the three MIC tests (see Table 1 ).
Murine infection model. All animal studies were approved by the Animal Research Committees of the University of Wisconsin and William S. Middleton Memorial VA Hospital. Six-week-old, specific-pathogenfree, female ICR/Swiss mice weighing between 24 and 27 g (Harlan Sprague-Dawley, Indianapolis, IN) were used for all studies. Three mice were utilized for each treatment and control group. Mice were rendered neutropenic (absolute neutrophil count of Ͻ100/mm 3 ) by injecting cyclophosphamide (Mead Johnson Pharmaceuticals, Evansville, IN) intraperitoneally 4 days (150 mg/kg of body weight) and 1 day (100 mg/kg) prior to experimental infection. Previous studies have shown that this regimen produces persistent neutropenia in this animal model for 5 days (3). Broth cultures of freshly plated bacteria were grown to logarithmic phase. The inoculum for each organism was diluted to a 0.3 absorbance at 580 nm. Viable plate count confirmation of the inoculum ranged from 10 6 to 10 7 CFU/ml. Animals were anesthetized by isoflurane inhalation. The mice were held upright, and 50 l of the inoculum was administered to the nares and inhaled into the lung. Treatment commenced 2 h after challenge, at which time mice had 6.24 Ϯ 0.40 log 10 CFU/lungs. Drug pharmacokinetics. Single-dose plasma pharmacokinetic (PK) studies were performed in infected mice given oral doses of linezolid (0.625, 2.5, 10, and 40 mg/kg) or TR-701 (0.625, 2.5, 10, and 40 mg/kg). Blood samples were obtained from groups of three mice at 0.25, 0.5, 1, 3, 6, 9, 12, and 24 h. The concentrations of compounds were analyzed by a validated liquid chromatography-tandem mass spectrometry (LC-MS-MS) by Midwest Bioresearch, Skokie, IL, as previously described (43) . The assay lower limit of quantitation was 1 ng/ml, and the coefficient of variation ranged from 1 to 7%. A noncompartmental model was used for PK analyses. PK parameters, including elimination half-life and concentration at time zero (C 0 ), were calculated via nonlinear least-squares techniques. The area under the concentration-time curve (AUC) was calculated by the trapezoidal rule. For treatment doses in which no kinetics were determined, the PK index was estimated by linear extrapolation for higher and lower dose levels and interpolation for dose levels within the dose range studied. Protein binding was previously determined by the sponsor, Trius Pharmaceuticals (85%).
Treatment protocols. Two hours after pulmonary challenge, mice were treated with either linezolid or TR-701. Linezolid was administered by oral gavage (OG) every 12 h over a dose range of 1.25 to 80 mg/kg. TR-701 was administered by OG every 12 h over a dose range of 0.625 to 160 mg/kg. Groups of three mice were utilized for each dose administered, 0-h and 24-h untreated controls. After 24 h of treatment the mice were mice. Each symbol represents the geometric mean Ϯ standard deviation (error bar) of the levels measured in three mice. Cmax, peak level in plasma; AUC, plasma AUC 0 -ϱ ; T1/2, plasma elimination half-life (in hours). PK parameters were not determined for the lowest dose of linezolid, as there were too few data points to estimate these parameters.
Tedizolid PD Target in an S. aureus Pneumonia Model euthanized by carbon dioxide asphyxiation. Untreated control mice were assessed at time of treatment initiation. Following euthanasia, the lungs were harvested using sterile technique, homogenized, diluted, plated, and incubated, and viable plate counts were assessed as previously described (18) . Data are expressed as the mean change in log 10 CFU/lungs for three mice per treatment group compared to the organism burden at the start of therapy. Data analysis. The results were analyzed using a sigmoid E max model: log 10 SD ϭ {log 10 [E/(E max Ϫ E)]/N } ϩ log ED 50 , where SD is the static dose or dose level necessary to maintain organism burden the same as at the start of treatment, E is the control growth, or in this case the log change in CFU/ml lung homogenate in untreated controls after 24 h, E max is the maximum effect, ED 50 is the dose required to achieve 50% of E max , and N is the slope of the dose-response curve. The indices E max , ED 50 , and N were calculated for each drug and strain using nonlinear least-squares regression. The dose needed to achieve net stasis (SD) and 1-log-unit kill was determined using the formula for each drug against each strain tested. The area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC/MIC ratio) has been shown in previous studies to be the pharmacodynamic (PD) parameter predictive of treatment efficacy for oxazolidinones (8, 35) . Therefore, the total drug AUC/MIC (tAUC/MIC ratio) and free drug (non-protein-bound) AUC/MIC (fAUC/MIC ratio) for each drug-organism combination was also determined. The coefficient of determination (R 2 ) was used to estimate the variance that could be due to regression with the drug exposure index. Analysis of variance (ANOVA) was used to determine whether the differences in PD target needed for stasis and killing were significant between linezolid and TR-700. The Mann-Whitney U test was used to compare TR-700 PD targets for MSSA and MRSA strain groups.
RESULTS
In vitro susceptibility testing. The MICs of linezolid and tedizolid (TR-700) are listed in Table 1 . The MICs for linezolid were the same for the five organisms tested, whereas the MICs for TR-700 varied by 8-fold (0.06 to 0.5 g/ml). In vitro potency was 4-to 32-fold higher for TR-700. Methicillin potency did not influence the linezolid or TR-700 MICs.
Pharmacokinetics. The time course plasma levels of linezolid and TR-700 in infected neutropenic mice after oral administration of 0.625, 2.5, 10, and 40 mg/kg are shown in Fig. 1 . PK parameters, including elimination half-life, maximum plasma drug concentration (C max ), and area under the drug-concentration curve from 0 h to infinity (AUC 0 -ϱ ) are also shown; however, these were not determined for the lowest linezolid dose (0.625 mg/kg), as there were too few data points to accurately calculate the parameters. The plasma pharmacokinetics of both drugs were linear over the dose range (R 2 of Ͼ99% based upon linear regression of AUC). The elimination half-life of linezolid ranged from 0.4 to 0.9 h. The C max increased from 0.6 to 30.0 mg/liter over the dose range, and the AUC ranged from 0.6 to 56.2 mg · h/liter. The elimination half-life of TR-700 ranged from 3.3 to 4.3 h. The C max increased from 0.2 to 20.1 mg/liter over the dose range, and the AUC ranged from 1.4 to 131 mg · h/liter. Protein binding values were previously reported for linezolid at 30% (51) . The binding value for TR-700 was based upon prior studies performed by the sponsor (85%).
Dose response, 24-h static dose, 1-log-unit kill determination. The dose-response curves following treatment with escalating doses of linezolid and tedizolid phosphate (TR-701) against 5 and 11 S. aureus isolates, respectively, are shown in Fig. 2 . At the start of therapy, mice had 6.24 Ϯ 0.40 log 10 CFU/lung. The organisms grew to 7.92 Ϯ 1.02 log 10 CFU/lung in untreated control mice over 24 h. The maximal reductions of burden in S. aureus-infected mice treated with linezolid and TR-701 were 3.27 Ϯ 0.56 log 10 CFU/lung and 3.93 Ϯ 0.24 log 10 CFU/lung, respectively. The dose-response curves for linezolid were nearly identical, as were the in vitro MICs. The MIC variation for TR-700 did appear to impact the dose-response relationship. Higher TR-701 doses were needed for similar effects against organisms with higher MICs compared to those with lower MICs. Tables 2 and 3 show the 24-h total dose required to achieve a static effect and 1-log-unit kill for linezolid and TR-701 against each S. aureus isolate. The mean plasma 24-h tAUC/MIC ratios associated with a static endpoint were 27.2 and 133 for linezolid and TR-700, respectively. However, when protein binding was considered, the mean plasma fAUC/MIC ratios for linezolid and TR-700 were similar at 19 and 20, respectively. The mean plasma 24-h fAUC/MIC associated with 1-log-unit kill reduction was roughly 2-fold higher than that needed for stasis (46.1 for linezolid and 34.6 for TR-700) and were not significantly different (P ϭ 0.334). Additionally, the plasma 24-h fAUC/MIC associated with net stasis and 1-log-unit kill was not significantly different in MSSA and MRSA isolates (P ϭ 0.41) for TR-700. The relationships between the AUC/MIC ratio and effect for linezolid and TR-700 are shown in Fig. 3 . The exposureresponse relationships were relatively strong based upon the coefficient of determination (R 2 ϭ 0.68 for linezolid and R 2 ϭ 0.48 for TR-700).
DISCUSSION
Antimicrobial pharmacokinetic-pharmacodynamic (PK/PD) studies are useful to identify the therapeutic potential of a drug through the integration of the PK properties, in vitro potency (MIC), and outcome. These approaches have proven useful in guiding design of effective drug regimens in humans and the development of susceptibility breakpoints (1, 2, 17, 21, 40, 41, 45). The emergence of antibiotic resistance has further elevated the relevance of these investigations to optimize treatment strategies. Drug resistance in Gram-positive organisms, especially S. aureus, has become epidemic worldwide and is linked to escalating morbidity and mortality (19, 20, 52, 54) . Among the infections produced by this pathogen, health care-and ventilator-associated pneumonia is associated with the most dismal outcomes, and S. aureus is now recognized as the most commonly implicated organism (28, 50) . Recent experimental and clinical investigations suggest the potential advantage of treatment with the oxazolidinone linezolid for this disease state due to potency against MRSA and penetration into the infection site relative to vancomycin and daptomycin (12, 16, 24, 30, 36, 38, (56) (57) (58) . The present studies were designed to characterize the PK/PD relationships of a new oxazolidinone, TR-701, for treatment of these infections. We further compared these PD relationships to those from a concurrent study of linezolid.
Prior PK/PD study with oxazolidinones, including TR-701, has demonstrated potency against both MSSA and MRSA and the relevance of the AUC/MIC index (2, 22, 23, 27, 34, 35, 37, 44, 53, 55) . For example, Louie et al. (35) performed a dose fractionation PK/PD evaluation of TR-701 against MRSA and MSSA using the murine thigh infection model. The total daily dose ranged from 0 to 100 mg/kg and was fractionated into every 24 h (q24h), q12h, and q6h dosing regimens. The dose-response curves were nearly identical for each dosing interval, suggesting that the amount of drug rather than the dosing frequency was most important for optimizing efficacy. Analysis of the dose fractionation data demonstrated that the AUC/MIC ratio was the driving PD index with the strongest regression fit (R 2 ϭ 0.98). While the index associated with therapeutic success has been extensively examined, few studies have attempted to identify the AUC/MIC magnitude or target associated with efficacy in treatment against MSSA or MRSA. In an in vivo study of linezolid using a neutropenic murine thigh infection model, the PD index AUC/ MIC provided the best correlation with efficacy and the static dose target was a fAUC/MIC of 58 (8) . A single clinical PK/PD study examined linezolid efficacy in patients with MRSA cellulitis, bacteremia, and pneumonia (44) . Clinical success was more common when the linezolid plasma fAUC/MIC value was near 30. More recently, the murine thigh infection model was used to explore the treatment efficacy of TR-701 against a single MRSA isolate (35) . Similar to linezolid, the AUC/MIC ratio was the predictive index for efficacy, and net stasis in infectious burden was noted at a fAUC/MIC of 43 at the 24-h study endpoint. The AUC/MIC stasis target identified in the current staphylococcal pneumonia studies was 2-to 4-fold lower than those reported in previous studies for both linezolid and TR-700 in soft tissue models. The stasis fAUC/MIC target in this study against nearly a dozen staphylococcal isolates was a value near 20. The similarity of the fAUC/MIC targets for both compounds when considering unbound drug (binding of 30% for linezolid versus 85% for TR-700) highlights the relevance of protein binding consideration when comparing PK/PD relationships across compounds within a similar mechanistic class (2, 17) . The TR-700 fAUC/MIC magnitude associated with the 1-log-unit killing endpoint was only 34.6. The mechanistic explanation for the difference in PD targets in this lung model compared to previous soft tissue models is not entirely clear. The designs of each of these studies were similar in many ways, including the mouse species, drug exposures (PK), and the neutropenic state of immunosuppression. One small difference was the level of protein binding utilized for calculating free drug (non-protein-bound) exposures. The current study used 85% as the protein-bound fraction, whereas the previous study used 80% (35) . Accounting for this difference alone would make the fAUC/MIC PD targets more congruent. Another key difference between the current and previous studies is the infection site. One intuitive theory to explain the discrepancy is the differential penetration of the oxazolidinones into the lung infection site (12, 16, 24, 26, 55 (26) . This PK difference at the infection site is a plausible explanation for the lower PD targets for oxazolidinones in pulmonary models compared to soft tissue models. The majority of antimicrobial PD investigations have shown that the PD target is similar in treatment of organisms exhibiting drug resistance. We explored this tenet by study of multiple S. aureus strains with beta-lactam, macrolide, and lincosamide resistance mechanisms. The treatment fAUC/MIC targets were congruent across these strain genotypes as previously described for other drug classes (4) (5) (6) (7) 47) .
A valuable application of preclinical PD studies is the ability to translate the results from preclinical animal model studies into the clinical realm to predict whether certain drug exposures in patients are likely to be successful for a given organism, site of infection, and MIC distribution. PK studies of healthy volunteers have been recently reported with TR-701 (10, 11, 39, 42) . Oral doses of 200 mg once a day produced an AUC between 22 and 26 mg · h/liter, whereas oral doses of 400 mg once daily produced an AUC between 54 and 56 mg · h/liter (10, 39, 42) . If one considers the free drug AUC associated with these doses, the highest MIC for which a stasis fAUC/MIC target of 20 would be achieved is approximately 0.5 mg/liter for a 400-mg once-daily regimen. The MIC ceiling associated with the 1-log-unit kill PD targets would be an MIC of 0.25 mg/liter. In vitro surveillance study with TR-700 for S. aureus has identified an MIC 50 and MIC 90 of 0.25 and 0.5 mg/liter, respectively (9, 14, 48, 59) .
In conclusion, the present study characterized the in vivo drug exposure response of a novel oxazolidinone, TR-701, in a neutropenic murine S. aureus pneumonia model. The results suggest that TR-701 would exhibit an efficacy similar to the efficacy of lin- ezolid for S. aureus pneumonia. An unanswered question in the current study is whether TR-701 would be expected to have the same efficacy for a linezolid-resistant isolate, as has been suggested by in vitro results (32, 33, 46, 49) . The results suggest further study of TR-701 in clinical trials of pneumonia due to S. aureus is warranted and may be especially useful given the increased burden of MSSA and MRSA pneumonia in the health care setting.
